Acumen Pharmaceuticals Q3 2024 Earnings Report $1.94 -0.02 (-1.02%) (As of 09:43 AM ET) Earnings HistoryForecast Acumen Pharmaceuticals EPS ResultsActual EPS-$0.50Consensus EPS -$0.36Beat/MissMissed by -$0.14One Year Ago EPS-$0.24Acumen Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAcumen Pharmaceuticals Announcement DetailsQuarterQ3 2024Date11/12/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptSlide DeckPress ReleaseABOS Earnings HistorySlide DeckFull Screen Slide DeckPowered by URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Acumen Pharmaceuticals Earnings HeadlinesAcumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx ConferenceNovember 26, 2024 | globenewswire.comAcumen Pharmaceuticals Advances Alzheimer’s TherapeuticNovember 14, 2024 | markets.businessinsider.comWill the Nasdaq 100 crash?In a world where some top money managers say you should “diversify” with a basket of stocks to help lower risk in your portfolio… And others say you should focus on only one ticker at a time because you can’t really keep detailed tabs on 10, 20 or more stocks at once… My #1 strategy to play the Nasdaq bull run has shown the power to provide the best of BOTH worlds at the same time. Because it harnesses ONE ticker that bottles up all the firepower of Apple, Nvidia, Tesla and more into one place… While I cannot promise future returns or against losses… This strategy targets major payouts OVERNIGHT!December 18, 2024 | DTI (Ad)Bank of America Securities Keeps Their Buy Rating on Acumen Pharmaceuticals (ABOS)November 14, 2024 | markets.businessinsider.comQ3 2024 Acumen Pharmaceuticals Inc Earnings CallNovember 13, 2024 | uk.finance.yahoo.comAcumen Pharmaceuticals Inc (ABOS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...November 13, 2024 | finance.yahoo.comSee More Acumen Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Acumen Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Acumen Pharmaceuticals and other key companies, straight to your email. Email Address About Acumen PharmaceuticalsAcumen Pharmaceuticals (NASDAQ:ABOS), a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.View Acumen Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
